Table 2 SABA and ICS prescribing post-SENTINEL Plus implementation compared with predicted prescribing based on pre-SENTINEL Plus prescribing levels.

From: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites

Descriptor

Total population

Practices with no additional SABA switch programme

Practices with additional SABA switch programme

Number of practices—n

25

16

9

Population size—n

456,135

267,451

188,684

Asthma patients—n

29,349

17,412

10,937

Total prescribing

Predicted prescribing (based on pre-SENTINEL baseline data)

Observed prescribing post-SENTINEL

Predicted prescribing (based on pre-SENTINEL baseline data)

Observed prescribing post-SENTINEL

Predicted prescribing (based on pre-SENTINEL baseline data)

Observed prescribing post-SENTINEL

SABA—n

192,954

182,473

129,376

120,064

63,578

62,407

- of which Salamol—n

4817

17,205

3706

5731

1111

11,474

ICS—n

204,504

210,482

132,152

135,948

72,352

74,534

Proportion SABA (%)

49%

46%

49%

47%

47%

46%

Change in prescribing post-SENTINEL Plus

Total population

Practices with no SABA switch programme

Practices with a SABA switch programme

SABA

All SABA—n

−10,481*

−9312**

−1171

% change from prev 12 m

−5.43%

−7.2%

−1.84%

- Salamol—n

+12,388*

+2025#

+10,363*

% change from prev 12 m

+257%

+55%

+933%

ICS

n

+5978#

+3796#

+2182#

% change from prev 12 m

+2.92%

+2.87%

+3.02%

Proportion SABA (%)

−3%

−2%

−1%

Change in prescribing post-SENTINEL Plus per practice per month

SABA—mean [95% CI]

−30.8 [−55.6 to −6.1]

−43.3 [−79.9 to −6.8]

−8.6 [−34.3 to 16.1]

ICS—mean [95% CI]

+19.0 [9.7 to 28.4]

+18.3 [4.5 to 32.0]

+20.4 [7.4 to 33.4]

  1. Statistical analysis undertaken using paired t-tests to compare prescribing before and after SENTINEL Plus implementation: *p < 0.05, **p = 0.05, #p ≤ 0.01.
Back to article page